Bide Pharmatech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	1,270	1,102	1,092	833.8	606.05	391.19
Other Revenue	0.01	0.01	0.03	0.03	0.17	0.28
Revenue	1,270	1,102	1,092	833.83	606.22	391.46
Revenue Growth (YoY)	15.62%	0.93%	30.95%	37.55%	54.86%	57.47%
Cost of Revenue	746.96	680.35	673.38	471.29	315.89	187.32
Gross Profit	522.79	421.66	418.48	362.54	290.33	204.14
Selling, General & Admin	278.04	244.87	250.12	167.26	145.16	105.42
Research & Development	56.13	55.62	59.72	43.46	32.1	18.39
Other Operating Expenses	5.82	6.71	5.01	3.96	2.42	1.98
Operating Expenses	341.9	308.96	319.18	218.2	182.75	128.03
Operating Income	180.89	112.71	99.3	144.34	107.58	76.11
Interest Expense	-3.71	-3.32	-2.53	-2.16	-0.92	-1.87
Interest & Investment Income	18.47	23.74	31.74	8.86	3.9	0.76
Currency Exchange Gain (Loss)	4.99	4.99	5.93	12.55	-6.67	-7.27
Other Non Operating Income (Expenses)	-5.3	-4.12	-2.5	-2.23	-1.08	-1.36
EBT Excluding Unusual Items	195.33	134	131.95	161.35	102.8	66.36
Gain (Loss) on Sale of Investments	2.63	3.15	-12.63	-0.46	-	-
Gain (Loss) on Sale of Assets	4.12	1.15	0.44	-	7.92	0.09
Asset Writedown	-6.42	-0.03	-0	-0	-0.04	-0.55
Other Unusual Items	9.52	9.74	6.25	10.88	3.87	4.37
Pretax Income	205.19	148.02	126	171.77	114.56	70.27
Income Tax Expense	51.89	30.59	17.55	25.8	16.99	11.27
Earnings From Continuing Operations	153.31	117.43	108.45	145.97	97.57	59
Minority Interest in Earnings	-	-	1.13	-	-	-
Net Income	153.31	117.43	109.57	145.97	97.57	59
Net Income to Common	153.31	117.43	109.57	145.97	97.57	59
Net Income Growth	91.57%	7.17%	-24.94%	49.60%	65.37%	-
Shares Outstanding (Basic)	88	89	91	74	67	62
Shares Outstanding (Diluted)	88	89	91	74	67	62
Shares Change (YoY)	-2.03%	-1.76%	22.83%	10.09%	8.03%	610.24%
EPS (Basic)	1.75	1.32	1.21	1.98	1.46	0.95
EPS (Diluted)	1.75	1.32	1.21	1.98	1.46	0.95
EPS Growth	95.55%	9.09%	-38.89%	35.89%	53.38%	-
Free Cash Flow	39.45	69.97	-118.47	-8.54	-94.09	-34.08
Free Cash Flow Per Share	0.45	0.79	-1.31	-0.12	-1.41	-0.55
Dividend Per Share	0.900	0.900	0.900	1.100	-	-
Dividend Growth	-	-	-18.18%	-	-	-
Gross Margin	41.17%	38.26%	38.33%	43.48%	47.89%	52.15%
Operating Margin	14.25%	10.23%	9.09%	17.31%	17.75%	19.44%
Profit Margin	12.07%	10.66%	10.04%	17.51%	16.10%	15.07%
Free Cash Flow Margin	3.11%	6.35%	-10.85%	-1.02%	-15.52%	-8.71%
EBITDA	192.75	123.58	108.85	150.15	111.51	78.59
EBITDA Margin	15.18%	11.21%	9.97%	18.01%	18.39%	20.08%
D&A For EBITDA	11.86	10.87	9.55	5.81	3.93	2.48
EBIT	180.89	112.71	99.3	144.34	107.58	76.11
EBIT Margin	14.25%	10.23%	9.09%	17.31%	17.75%	19.44%
Effective Tax Rate	25.29%	20.67%	13.93%	15.02%	14.83%	16.04%
Revenue as Reported	1,270	1,102	1,092	833.83	606.22	-
Advertising Expenses	-	9.59	7.77	5.65	5.87	3.71

Source: S&P Global Market Intelligence. Standard template. Financial Sources.